Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Nov 15;98(10):2259–2267. doi: 10.1172/JCI119036

In the absence of the low density lipoprotein receptor, human apolipoprotein C1 overexpression in transgenic mice inhibits the hepatic uptake of very low density lipoproteins via a receptor-associated protein-sensitive pathway.

M C Jong 1, V E Dahlmans 1, P J van Gorp 1, K W van Dijk 1, M L Breuer 1, M H Hofker 1, L M Havekes 1
PMCID: PMC507675  PMID: 8941642

Abstract

To study the role of apoC1 in lipoprotein metabolism, we have generated transgenic mice expressing the human APOC1 gene. On a sucrose-rich diet, male transgenic mice with high APOC1 expression in the liver showed elevated levels of serum cholesterol and triglyceride compared with control mice (5.7+/-0.7 and 3.3+/-2.1 vs. 2.7+/-0.1 and 0.4+/-0.1 mmol/liter, respectively). These elevated levels were mainly confined to the VLDL fraction. Female APOC1 transgenic mice showed less pronounced elevated serum lipid levels. In vivo VLDL turnover studies revealed that, in hyperlipidemic APOC1 transgenic mice, VLDL particles are cleared less efficiently from the circulation as compared with control mice. No differences were observed in the hepatic production and extrahepatic lipolysis of VLDL-triglyceride. Also, VLDL isolated from control and APOC1 transgenic mice were found to be equally good substrates for bovine lipoprotein lipase in vitro. These data indicate that the hyperlipidemia in APOC1 transgenic mice results primarily from impaired hepatic VLDL particle clearance, rather than a defect in the hydrolysis of VLDL-triglyceride. To investigate which hepatic receptor is involved in the apoC1-mediated inhibition of VLDL clearance, APOC1 transgenic mice were bred with an LDL receptor-deficient (LDLR(-/-)) background. In addition, control, LDLR(-/-), and LDLR(-/-)/APOC1 mice were transfected with adenovirus carrying the gene for the receptor-associated protein (Ad-RAP). Both serum cholesterol and triglyceride levels were strongly elevated in LDLR(-/-)/APOC1 mice compared with LDLR(-/-) mice (52+/-19 and 36+/-19 vs. 8.4+/-0.9 and 0.5+/-0.2 mmol/liter, respectively), indicating that apoC1 inhibits the alternative VLDL clearance pathway via the remnant receptor. Transfection of LDLR(-/-) mice with Ad-RAP strongly increased serum cholesterol and triglyceride levels, but to a lesser extent than those found in LDLR(-/-)/APOC1 mice (39+/-8 and 17+/-8 vs. 52+/-19 and 36+/-19 mmol/liter, respectively). However, in LDLR(-/-)/APOC1 mice the transfection with Ad-RAP did not further increase serum cholesterol and triglyceride levels (52+/-19 and 36+/-19 vs. 60+/-10 and 38+/-7 mmol/liter, respectively). From these studies we conclude that, in the absence of the LDLR, apoC1 inhibits the hepatic uptake of VLDL via a RAP-sensitive pathway.

Full Text

The Full Text of this article is available as a PDF (233.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aalto-Setälä K., Fisher E. A., Chen X., Chajek-Shaul T., Hayek T., Zechner R., Walsh A., Ramakrishnan R., Ginsberg H. N., Breslow J. L. Mechanism of hypertriglyceridemia in human apolipoprotein (apo) CIII transgenic mice. Diminished very low density lipoprotein fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J Clin Invest. 1992 Nov;90(5):1889–1900. doi: 10.1172/JCI116066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. BLIGH E. G., DYER W. J. A rapid method of total lipid extraction and purification. Can J Biochem Physiol. 1959 Aug;37(8):911–917. doi: 10.1139/o59-099. [DOI] [PubMed] [Google Scholar]
  3. Brown W. V., Baginsky M. L. Inhibition of lipoprotein lipase by an apoprotein of human very low density lipoprotein. Biochem Biophys Res Commun. 1972 Jan 31;46(2):375–382. doi: 10.1016/s0006-291x(72)80149-9. [DOI] [PubMed] [Google Scholar]
  4. Choi S. Y., Cooper A. D. A comparison of the roles of the low density lipoprotein (LDL) receptor and the LDL receptor-related protein/alpha 2-macroglobulin receptor in chylomicron remnant removal in the mouse in vivo. J Biol Chem. 1993 Jul 25;268(21):15804–15811. [PubMed] [Google Scholar]
  5. Choi S. Y., Fong L. G., Kirven M. J., Cooper A. D. Use of an anti-low density lipoprotein receptor antibody to quantify the role of the LDL receptor in the removal of chylomicron remnants in the mouse in vivo. J Clin Invest. 1991 Oct;88(4):1173–1181. doi: 10.1172/JCI115419. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Fallaux F. J., Kranenburg O., Cramer S. J., Houweling A., Van Ormondt H., Hoeben R. C., Van Der Eb A. J. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther. 1996 Jan 20;7(2):215–222. doi: 10.1089/hum.1996.7.2-215. [DOI] [PubMed] [Google Scholar]
  7. Fort P., Marty L., Piechaczyk M., el Sabrouty S., Dani C., Jeanteur P., Blanchard J. M. Various rat adult tissues express only one major mRNA species from the glyceraldehyde-3-phosphate-dehydrogenase multigenic family. Nucleic Acids Res. 1985 Mar 11;13(5):1431–1442. doi: 10.1093/nar/13.5.1431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Havel R. J. Chylomicron remnants: hepatic receptors and metabolism. Curr Opin Lipidol. 1995 Oct;6(5):312–316. doi: 10.1097/00041433-199510000-00011. [DOI] [PubMed] [Google Scholar]
  9. Havel R. J., Fielding C. J., Olivecrona T., Shore V. G., Fielding P. E., Egelrud T. Cofactor activity of protein components of human very low density lipoproteins in the hydrolysis of triglycerides by lipoproteins lipase from different sources. Biochemistry. 1973 Apr 24;12(9):1828–1833. doi: 10.1021/bi00733a026. [DOI] [PubMed] [Google Scholar]
  10. Herz J., Gerard R. D. Adenovirus-mediated transfer of low density lipoprotein receptor gene acutely accelerates cholesterol clearance in normal mice. Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2812–2816. doi: 10.1073/pnas.90.7.2812. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Herz J., Willnow T. E. Lipoprotein and receptor interactions in vivo. Curr Opin Lipidol. 1995 Apr;6(2):97–103. doi: 10.1097/00041433-199504000-00007. [DOI] [PubMed] [Google Scholar]
  12. Hoffer M. J., van Eck M. M., Havekes L. M., Hofker M. H., Frants R. R. The mouse apolipoprotein C1 gene: structure and expression. Genomics. 1993 Oct;18(1):37–42. doi: 10.1006/geno.1993.1424. [DOI] [PubMed] [Google Scholar]
  13. Horiuchi K., Tajima S., Menju M., Yamamoto A. Structure and expression of mouse apolipoprotein E gene. J Biochem. 1989 Jul;106(1):98–103. doi: 10.1093/oxfordjournals.jbchem.a122828. [DOI] [PubMed] [Google Scholar]
  14. Ishibashi S., Brown M. S., Goldstein J. L., Gerard R. D., Hammer R. E., Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J Clin Invest. 1993 Aug;92(2):883–893. doi: 10.1172/JCI116663. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Jong M. C., Dahlmans V. E., van Gorp P. J., Breuer M. L., Mol M. J., van der Zee A., Frants R. R., Hofker M. H., Havekes L. M. Both lipolysis and hepatic uptake of VLDL are impaired in transgenic mice coexpressing human apolipoprotein E*3Leiden and human apolipoprotein C1. Arterioscler Thromb Vasc Biol. 1996 Aug;16(8):934–940. doi: 10.1161/01.atv.16.8.934. [DOI] [PubMed] [Google Scholar]
  16. Kowal R. C., Herz J., Goldstein J. L., Esser V., Brown M. S. Low density lipoprotein receptor-related protein mediates uptake of cholesteryl esters derived from apoprotein E-enriched lipoproteins. Proc Natl Acad Sci U S A. 1989 Aug;86(15):5810–5814. doi: 10.1073/pnas.86.15.5810. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  18. Moir A. M., Zammit V. A. Selective labelling of hepatic fatty acids in vivo. Studies on the synthesis and secretion of glycerolipids in the rat. Biochem J. 1992 Apr 1;283(Pt 1):145–149. doi: 10.1042/bj2830145. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Nishina P. M., Verstuyft J., Paigen B. Synthetic low and high fat diets for the study of atherosclerosis in the mouse. J Lipid Res. 1990 May;31(5):859–869. [PubMed] [Google Scholar]
  20. Quarfordt S. H., Michalopoulos G., Schirmer B. The effect of human C apolipoproteins on the in vitro hepatic metabolism of triglyceride emulsions in the rat. J Biol Chem. 1982 Dec 25;257(24):14642–14647. [PubMed] [Google Scholar]
  21. Sehayek E., Eisenberg S. Mechanisms of inhibition by apolipoprotein C of apolipoprotein E-dependent cellular metabolism of human triglyceride-rich lipoproteins through the low density lipoprotein receptor pathway. J Biol Chem. 1991 Sep 25;266(27):18259–18267. [PubMed] [Google Scholar]
  22. Shachter N. S., Hayek T., Leff T., Smith J. D., Rosenberg D. W., Walsh A., Ramakrishnan R., Goldberg I. J., Ginsberg H. N., Breslow J. L. Overexpression of apolipoprotein CII causes hypertriglyceridemia in transgenic mice. J Clin Invest. 1994 Apr;93(4):1683–1690. doi: 10.1172/JCI117151. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Shimano H., Namba Y., Ohsuga J., Kawamura M., Yamamoto K., Shimada M., Gotoda T., Harada K., Yazaki Y., Yamada N. Secretion-recapture process of apolipoprotein E in hepatic uptake of chylomicron remnants in transgenic mice. J Clin Invest. 1994 May;93(5):2215–2223. doi: 10.1172/JCI117218. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Shulman R. S., Herbert P. N., Wehrly K., Fredrickson D. S. Thf complete amino acid sequence of C-I (apoLp-Ser), an apolipoprotein from human very low density lipoproteins. J Biol Chem. 1975 Jan 10;250(1):182–190. [PubMed] [Google Scholar]
  25. Simonet W. S., Bucay N., Pitas R. E., Lauer S. J., Taylor J. M. Multiple tissue-specific elements control the apolipoprotein E/C-I gene locus in transgenic mice. J Biol Chem. 1991 May 15;266(14):8651–8654. [PubMed] [Google Scholar]
  26. Swaney J. B., Weisgraber K. H. Effect of apolipoprotein C-I peptides on the apolipoprotein E content and receptor-binding properties of beta-migrating very low density lipoproteins. J Lipid Res. 1994 Jan;35(1):134–142. [PubMed] [Google Scholar]
  27. Weisgraber K. H., Mahley R. W., Kowal R. C., Herz J., Goldstein J. L., Brown M. S. Apolipoprotein C-I modulates the interaction of apolipoprotein E with beta-migrating very low density lipoproteins (beta-VLDL) and inhibits binding of beta-VLDL to low density lipoprotein receptor-related protein. J Biol Chem. 1990 Dec 25;265(36):22453–22459. [PubMed] [Google Scholar]
  28. Willnow T. E., Armstrong S. A., Hammer R. E., Herz J. Functional expression of low density lipoprotein receptor-related protein is controlled by receptor-associated protein in vivo. Proc Natl Acad Sci U S A. 1995 May 9;92(10):4537–4541. doi: 10.1073/pnas.92.10.4537. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Willnow T. E., Sheng Z., Ishibashi S., Herz J. Inhibition of hepatic chylomicron remnant uptake by gene transfer of a receptor antagonist. Science. 1994 Jun 3;264(5164):1471–1474. doi: 10.1126/science.7515194. [DOI] [PubMed] [Google Scholar]
  30. Windler E., Havel R. J. Inhibitory effects of C apolipoproteins from rats and humans on the uptake of triglyceride-rich lipoproteins and their remnants by the perfused rat liver. J Lipid Res. 1985 May;26(5):556–565. [PubMed] [Google Scholar]
  31. Zannis V. I., McPherson J., Goldberger G., Karathanasis S. K., Breslow J. L. Synthesis, intracellular processing, and signal peptide of human apolipoprotein E. J Biol Chem. 1984 May 10;259(9):5495–5499. [PubMed] [Google Scholar]
  32. de Silva H. V., Lauer S. J., Wang J., Simonet W. S., Weisgraber K. H., Mahley R. W., Taylor J. M. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E. J Biol Chem. 1994 Jan 21;269(3):2324–2335. [PubMed] [Google Scholar]
  33. van Dijk M. C., Boers W., Linthorst C., van Berkel T. J. Role of the scavenger receptor in the uptake of methylamine-activated alpha 2-macroglobulin by rat liver. Biochem J. 1992 Oct 15;287(Pt 2):447–455. doi: 10.1042/bj2870447. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. van Ree J. H., Hofker M. H., van den Broek W. J., van Deursen J. M., van der Boom H., Frants R. R., Wieringa B., Havekes L. M. Increased response to cholesterol feeding in apolipoprotein C1-deficient mice. Biochem J. 1995 Feb 1;305(Pt 3):905–911. doi: 10.1042/bj3050905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  35. van Ree J. H., van den Broek W. J., Dahlmans V. E., Groot P. H., Vidgeon-Hart M., Frants R. R., Wieringa B., Havekes L. M., Hofker M. H. Diet-induced hypercholesterolemia and atherosclerosis in heterozygous apolipoprotein E-deficient mice. Atherosclerosis. 1994 Nov;111(1):25–37. doi: 10.1016/0021-9150(94)90188-0. [DOI] [PubMed] [Google Scholar]
  36. van Vlijmen B. J., van 't Hof H. B., Mol M. J., van der Boom H., van der Zee A., Frants R. R., Hofker M. H., Havekes L. M. Modulation of very low density lipoprotein production and clearance contributes to age- and gender- dependent hyperlipoproteinemia in apolipoprotein E3-Leiden transgenic mice. J Clin Invest. 1996 Mar 1;97(5):1184–1192. doi: 10.1172/JCI118532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. van Vlijmen B. J., van den Maagdenberg A. M., Gijbels M. J., van der Boom H., HogenEsch H., Frants R. R., Hofker M. H., Havekes L. M. Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest. 1994 Apr;93(4):1403–1410. doi: 10.1172/JCI117117. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. van den Maagdenberg A. M., Hofker M. H., Krimpenfort P. J., de Bruijn I., van Vlijmen B., van der Boom H., Havekes L. M., Frants R. R. Transgenic mice carrying the apolipoprotein E3-Leiden gene exhibit hyperlipoproteinemia. J Biol Chem. 1993 May 15;268(14):10540–10545. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES